Composition and methods for predicting necrotizing enterocolitis in preterm infants
AssigneeUniversity of Maryland, Baltimore
InventorsBing Ma, Rose Viscardi, Jacques Ravel
Life of this patent
Estimating the term…
Abstract
A correlative finding between increased Clostridiales and/or Bifidobacteriales bacterial abundance in the gut and intestinal barrier maturation of preterm neonates at-risk for development of necrotizing enterocolitis (NEC) is disclosed. These findings form the basis for the methods of identifying preterm infants at risk for developing necrotizing enterocolitis (NEC), the methods of treating such infants, as well as the methods of characterizing intestinal permeability in preterm infants disclosed herein.
Claims26
A method of treating or preventing high intestinal permeability in a subject comprising:
- (a) determining the amount of Clostridiales and/or Bifidobacteriales bacteria in a sample obtained from a subject, and administering a therapeutically effective amount of a treatment or preventive agent for high intestinal permeability (IP) to the subject when the amount of Clostridiales and/or Bifidobacteriales bacteria in the sample is about 5% or less by relative abundance of the total amount of bacteria;
- or
- (b) determining the amount of Clostridiales and/or Bifidobacteriales bacteria in samples obtained from a subject at two or more time points and administering a therapeutically effective amount of a treatment or preventive agent for high intestinal permeability to the subject when the amount of Clostridiales and/or Bifidobacteriales bacteria in the samples decreases over time.
A method of treating or preventing high intestinal permeability in a subject comprising:
- (a) determining the amount of Clostridiales bacteria in a sample obtained from a subject, and administering a therapeutically effective amount of a treatment or preventive agent for high intestinal permeability (IP) to the subject when the amount of Clostridiales and/or Bifidobacteriales bacteria in the sample is about 5% or less by relative abundance of the total amount of bacteria;
- (b) determining the amount of Clostridiales bacteria in a sample obtained from a subject, and administering a therapeutically effective amount of a treatment or preventive agent for high intestinal permeability to the subject when the amount of Clostridiales and/or Bifidobacteriales bacteria is within a pre-established range of amounts of Clostridiales and/or Bifidobacteriales bacteria associated with high intestinal permeability;
- or
- (c) determining the amount of Clostridiales bacteria in samples obtained from a subject at two or more time points and administering a therapeutically effective amount of a treatment or preventive agent for high intestinal permeability to the subject when the amount of Clostridiales and/or Bifidobacteriales bacteria in the samples decreases over time.
Dependencies are inferred from the claim text.